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OBJECTIVES: Hereditary angioedema (HAE) is a rare and potentially life-threaten-
ing condition. The efficacy of acute HAE treatments has not been assessed in head-
to-head comparative studies. This study aimed to establish the relative efficacy of
icatibant [Shire HGT] versus C1-esterase inhibitor concentrate (C1-INH) [CSL Beh-
ring], C1-INH [ViroPharma], rh-C1-INH [Pharming], and ecallantide [Dyax].
METHODS: A systematic literature review identified nine relevant randomised
clinical trials. Indirect comparison (IC) hazard ratios (HR) between treatments were
calculated using the methods of Bucher et al (1997) and Song et al (2003). To account
for trial heterogeneity, five sets of icatibant data were considered separately; three
clinical endpoint definitions (time to onset of primary symptom relief, time to
initial symptom improvement [subject-assessed], and time to onset of symptom
relief based on composite VAS score); and three rescue medication (RM) censoring
methods (no censoring [RMs ignored], censoring subjects who took RMs prior to
onset of symptom relief, and resetting time to onset of symptom relief to 24 h for
censored subjects) were considered separately in the ICs. RESULTS: The IC consid-
ered each of the 45 icatibant data/endpoint definition/RM censoring combinations.
HR estimates favoured (HR 1) 37/45 icatibant combinations versus C1-INH [CSL
Behring] 20 IU/kg (Median HR  1.39 [minimum 0.72, maximum 2.10]), 45/45 (29
statistically significant) versus C1-INH [CSL Behring] 10 IU/kg (Median HR  2.19
[minimum 1.07, maximum 3.39]), 32/45 versus C1-INH [ViroPharma] (Median HR 
1.36 [minimum 0.63, maximum 2.22]), 24/45 versus rh-C1-INH 50 IU/kg (Median HR
 1.04 [minimum 0.48, maximum 1.70]), and 43/45 versus ecallantide (Median HR
1.67 [minimum 0.75, maximum 2.66]). CONCLUSIONS: Icatibant showed improved
time to symptom relief when compared with C1-INH [CSL Behring] 10 IU/kg. No
clear differences were evident versus either C1-INH [CSL Behring] 20 IU/kg (SmPC
dosing) or the three other HAE treatments.
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OBJECTIVES: Due to limited patient population and scarcity of real-world data,
performing health economic analyses in haemophilia patients with inhibitors is
challenging. A recent publication based on national data from the Czech Republic
presented a health economic comparison of recombinant activated factor VII (rF-
VIIa) and plasma-derived activated prothrombin complex concentrate (pd-aPCC) in
the treatment of bleedings in inhibitor patients. The objective of this study was to
adapt the findings from the Czech study to a Swedish setting. METHODS: Aggre-
gated published data were used for the analysis. Real-life resource utilization (by-
passing agents and hospitalizations) were derived from the Czech study. Swedish
costs were obtained by multiplying each resource with corresponding unit costs
obtained from public price lists. RESULTS: Mean dose per bleeding in the rFVIIa
group was 17000 mcg, while the corresponding figure for the pd-aPCC group was
23000 IU. Mean number of hospital days was 0.9 in the rFVIIa group and 3.2 in the
pd-aPCC group. Mean total cost per bleeding was almost twice as high in the pd-
aPCC group (SEK 225549) compared to the rFVIIa group (SEK 112298). There was a
large variability in resource use across bleeding episodes in both treatment groups.
CONCLUSIONS: The Swedish adaptation of the Czech health economic analysis of
rFVIIa and pd-aPCC showed that rFVIIa treatment was associated with substan-
tially lower costs per bleeding episode. The main limitation of this analysis in a
Swedish setting is that it is based on data from the Czech Republic. However, Czech
data should have relevance in a Swedish setting, considering the large similarities
between the countries regarding incidence and severity of the disease, manage-
ment of haemophilia, availability of health care resources, clinical practice pat-
terns, and relative prices. A strength of the analysis is that it is based on real-life
data.
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OBJECTIVES: Innovative treatments have transformed CML into a chronic disease
mostly managed in outpatient care. This study aimed to estimate the cost of treat-
ing patients with CML as well as the cost of managing the adverse events of the
disease. METHODS: A retrospective study was performed in the Heamatology De-
partment of Evangelismos General Hospital of Athens. Study sample consisted of
all patients (n79) who visited the hematology of outpatient Units of the hospital
from January 2007 to December 2011. Cost analysis was based on patient’s direct
cost, including cost of personnel, supplies, medication, laboratory and imaging
tests, infrastructure and various other on-site costs. Mean annual cost per patient
is elaborated separately in outpatient and inpatient care. Inpatient costs mostly
refer to the treatment of adverse events. Cost analysis is based on each year’s NHS
prices transformed in 2012 values and the National Health System (NHS) persective
has been used. RESULTS: The mean annual cost per patient in chronic phase of
Myeloid Leukemia treated in outpatient care is estimated at €22.972. The most
frequent adverse events managed were anemia (n7, 9% of patients) and neutro-
penia (n12, 15% of patients). Mean hospitalization cost per patient due to the
treatment of adverse events is as follows: for anemia €2.193 and neutropenia of
€1.312. The cost of treating anemia corresponds to 9.5% of the overall cost of treat-
ment and the cost of neutropenia about 5,7%. Annual cost of newly diagnosed
patients in 2011 was estimated at €8.339, 57% lower than the respective cost of
patients treated in 2007 (€14.652). CONCLUSIONS: Innovative treatments for CML
have resulted in treating patients in outpatient care with lower adverse events and
consequently lower cost. Under the current economic restriction Greece is facing
as well as the recent implementation of Diagnoses Related Groups, information on
treatment costs provides a tool to assess NHS hospitals’ performance.
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OBJECTIVES: To analyze the direct and indirect cost of therapy of chronic myeloid
leukemia (CML) from the society perspective within one year. METHODS: It is a
prospective observational cost study of 36 patients treated at the University Hos-
pital “Alexandrovska”. The pharmacotherapy cost, GP and specialists visits cost,
hospitalization cost were collected as direct medical costs. National health insur-
ance fund and hospital tariff were used as unit cost sources. Days out of work were
also collected and multiplied with the average monthly income to gather the indi-
rect costs. RESULTS: The observed 36 patients (average age 51 years) remain 14% of
all diagnosed and actively treated CML population. Average monthly cost of ther-
apy is 3130 Euro (SD 775 Euro) thus reaching 37 560 Euro per year per patient. On
imatinib therapy were found 20 of the observed patients, 8 on dasatinib, and 2 on
nilotinib. 6 patients were switched to different medicine during the period, out of
them 5 from imatinib to nilotinib due to disease progression and 1 from imatinib to
dasatinib due to intolerance development. On average 5 visits were performed per
year to GP and from 4-12 to specialists. The cost of the respective visits is 18 (SD5),
and 34 euro per patient. Only 6 patients were hospitalized during the therapy
switch and their cost was found to be 1098 Euro. The total number of days out of
work was found to be 103 days for the employed patients thus consuming incomes
for 5 months. Relative share of the direct and indirect cost is 92% to 8%, respec-
tively. Out of the direct medical cost medicines account for near 90%.
CONCLUSIONS: CML consumes mainly direct medical costs where the medicines
are the main cost driver.
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OBJECTIVES: Acute Myeloid Leukaemia (AML) can be diagnosed at any age and
accounts for approximately one third of all leukaemia diagnoses. Treatment,
which can be given with supportive and/or curative intent, is considered expensive
compared to other cancers. Despite this, no long-term predictive models have been
developed for AML, mainly due to the complexities associated with this disease.
Thus, the aim of the current study was to develop an AML model (based on a UK
cohort) that would allow cost and life expectancy results to be expressed at popu-
lation level. METHODS: The model developed in this study combined a decision
tree with several Markov models. This was in order to reflect the complexity of
health states, treatments, and prognostic factors (such as age and response to
chemotherapy) of AML. The model was simulated over a life cycle of 60 months and
results were contrasted between two age-groups and over different treatment
pathways. Probabilistic modelling was also implemented in order to capture the
potential uncertainties of input parameters. Transition probabilities, life expectan-
cies and costs were derived from the NHS Hospital Episode Statistics (HES) and a UK
population-based database from the Haematological Malignancy Research Net-
work (HMRN, www.hmrn.org). RESULTS: The expected five year medical cost and
life expectancy for the elderly patients (60) were £22,538 and 8.5 months respec-
tively, and for the young adult patients (18-60) £82,266 and 33.78 months respec-
tively. The model was validated by the fact that the predicted results captured 92%
of the actual costs, while it also demonstrated good fit of the actual survival
outcomes. CONCLUSIONS: Costs and life expectancy of AML vary according to
patient characteristics and treatment pathways. It is expected that future applica-
tion of the AML model developed in this study could be used to evaluate new
diagnostic tools/treatments and to support health care decision makers.
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OBJECTIVES: To quantify the work productivity loss induced by chronic immune-
mediated inflammatory diseases. METHODS: A systematic and computerized
search was performed in the literature published in English from 2000 to 2011 in
Pubmed. The search terms were: ‘crohn disease’, ‘spondylitis, ‘ankylosing’, ‘psori-
asis’, ‘rheumatoid arthritis’, ‘work productivity’, ‘productivity’, ‘absenteeism’, ‘sick
leave’ and ‘employment status’. Number of days of absenteeism and presenteeism,
and their estimated costs were extracted. Mean duration of work productivity loss
per patient was annualized. Mean costs per patient were annualized, converted in
Euros and actualized to 2010 using exchange rates and price indexes provided by
the Organisation for Economic Co-operation and Development. RESULTS: Eighteen
publications were analyzed: 4 for rheumatoid arthritis, 6 for ankylosing spondyli-
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